Zolmitriptan

Introduction Overview

Generic Name

zolmitriptan

Brand Name

Zomig

Dosage Form

Oral tablet, orally disintegrating tablet, nasal spray

Drug Class

Antimigraine agents

Pharmacokinetics

Absorption:
Zolmitriptan is rapidly absorbed following oral administration, with peak plasma concentrations typically reached within 1.5 to 2 hours after dosing. The orally disintegrating tablet (Zomig-ZMT) offers absorption comparable to the standard oral tablet, facilitating rapid onset of action. The nasal spray formulation allows for absorption primarily through the nasal mucosa, leading to faster absorption and onset of action compared to oral formulations, with peak plasma levels reached approximately 15 to 30 minutes post-dose. Food intake does not significantly affect the absorption of zolmitriptan; however, the presence of gastrointestinal symptoms during migraine may influence drug bioavailability. The bioavailability of oral zolmitriptan is estimated to be about 40%, largely due to first-pass hepatic metabolism.

Distribution:
Zolmitriptan exhibits moderate plasma protein binding, approximately 25%, indicating that a significant proportion of the drug remains unbound and pharmacologically active in circulation. The volume of distribution approximates 8 liters, reflecting moderate tissue distribution. The drug crosses the blood-brain barrier to exert its central effects on cerebral blood vessels and neuronal receptors involved in migraine pathophysiology. Zolmitriptan is distributed into systemic circulation with minimal accumulation in peripheral tissues, supporting its targeted action profile.

Metabolism:
Zolmitriptan undergoes extensive hepatic metabolism primarily via the cytochrome P450 enzyme CYP1A2. It is metabolized into an active N-desmethyl metabolite, which contributes roughly 30% of the pharmacologic activity of the parent compound. The hepatic metabolic processing is subject to individual variation, influenced by genetic polymorphisms and concomitant medications that inhibit or induce CYP1A2. Monoamine oxidase (MAO) enzymes also have a role in metabolism; therefore, coadministration with MAO inhibitors is contraindicated due to potentially elevated zolmitriptan levels and risk of toxicity.

Elimination:
Elimination of zolmitriptan occurs predominantly via renal excretion, both as unchanged drug and metabolites. The elimination half-life ranges from approximately 3 to 4 hours, with a majority cleared within 24 hours. Renal impairment may prolong elimination, necessitating dose adjustments or caution in patients with compromised kidney function. Fecal excretion accounts for a minor route of elimination. The pharmacokinetic profile supports twice-daily dosing with a maximum 24-hour dose limit of 10 mg to avoid accumulation and minimize adverse effects.

Dosage Forms

Available Dosage Forms:
- Oral tablet: 1.25 mg, 2.5 mg (scored tablet can be halved to obtain 1.25 mg dose)
- Orally disintegrating tablet (Zomig-ZMT): 2.5 mg (not scored, should not be broken)
- Nasal spray: 2.5 mg per spray

Dosages for Adults and Adolescents:
- Adults:
* Oral tablet: Initial dose 1.25 or 2.5 mg orally once; may repeat after 2 hours if headache persists or returns.
* Orally disintegrating tablet: 2.5 mg orally once; may repeat after 2 hours.
* Nasal spray: 2.5 mg intranasally once; may repeat after 2 hours.
* Maximum single dose: 5 mg.
* Maximum total daily dose: 10 mg within 24 hours.
- Pediatric (age 12 and older):
* Nasal spray: Initial dose 2.5 mg intranasally; may repeat after 2 hours if needed.
* Maximum daily dose: 10 mg in 24 hours.

Specific Patient Populations:
- In patients with hepatic or renal impairment, caution is advised and dose adjustments may be necessary.
- Use in pediatric patients under 12 years is not approved.
- Use cautiously in patients with cardiovascular risk factors and monitor heart function closely.
- Orally disintegrating tablets contain phenylalanine; should be used cautiously in patients with phenylketonuria (PKU).

Mechanism Of Action

Zolmitriptan is a selective agonist of serotonin 5-HT1B and 5-HT1D receptors, which are key receptors involved in migraine pathophysiology. By stimulating these receptors on intracranial blood vessels, zolmitriptan induces vasoconstriction of dilated cranial blood vessels, counteracting the vasodilation that is implicated in migraine attacks. This vasoconstrictive effect reduces the distension and pressure thought to trigger migraine pain.

Beyond vascular effects, zolmitriptan modulates neuronal pathways within the trigeminovascular system. Activation of 5-HT1D receptors on trigeminal nerve endings inhibits the release of pro-inflammatory neuropeptides such as calcitonin gene-related peptide (CGRP), substance P, and neurokinin A. These neuropeptides contribute to neurogenic inflammation and sensitization of pain pathways in migraine. By inhibiting their release, zolmitriptan mitigates inflammation and diminished neuronal hyperexcitability.

At the cellular level, agonism of 5-HT1B/1D receptors results in reduced cyclic AMP production and decreased intracellular calcium influx, leading to suppression of neurotransmitter release and attenuation of nociceptive signaling. The combined vascular and neuronal actions provide a dual mechanism by which zolmitriptan aborts migraine attacks.

Clinical studies have demonstrated the efficacy of zolmitriptan in achieving rapid headache relief, typically within 1 to 2 hours post-dose. When compared to other triptans like sumatriptan, zolmitriptan offers similar effectiveness but with different pharmacokinetic profiles and routes of administration, such as the convenience of orally disintegrating tablets and nasal spray, providing options for patients with nausea or vomiting during migraine.

Pharmacological Actions

Selective agonism at serotonin 5-HT1B and 5-HT1D receptors.
Vasoconstriction of dilated intracranial arteries involved in migraine.
Inhibition of pro-inflammatory neuropeptide release (CGRP, substance P) from trigeminal nerve endings.
Reduction of neurogenic inflammation and neuronal sensitization.
Modulation of pain pathways in the central nervous system.
Rapid onset of action with oral, disintegrating tablet, and nasal spray formulations.
Minimal systemic side effects due to selective receptor targeting.
Effective abortive therapy for migraine with or without aura.
Metabolic conversion to an active N-desmethyl metabolite contributing to pharmacologic activity.

Therapeutic Or Clinical Uses

Acute treatment of migraine attacks with or without aura in adults.
Relief of associated migraine symptoms including headache pain, nausea, photophobia, and phonophobia.
Alternative treatment for patients who cannot tolerate oral medications due to nausea or vomiting via nasal spray or orally disintegrating tablet.
Abortive therapy intended for use at migraine onset for optimal efficacy.
Use in adolescents 12 years and older for nasal spray formulation for migraine relief.
Treatment of migraine attacks where other triptans are contraindicated or ineffective.
Management option in patients requiring rapid and effective symptomatic relief.
Component of multimodal migraine management when used alongside non-pharmacologic strategies.
Clinical use limited to diagnosed migraine; not effective for tension headaches or other headache types.

Side Or Adverse Effects

Chest pain or tightness in throat, neck, or chest, potentially indicative of vasospasm.
Flushing or warm sensation and redness of the skin.
Drowsiness or fatigue following administration.
Dry mouth and gastrointestinal upset including nausea or stomach discomfort.
Pounding or rapid heartbeat (palpitations).
Dizziness or lightheadedness especially on standing.
Serotonin syndrome symptoms such as agitation, hallucinations, fever, and loss of coordination when combined with serotonergic drugs.
Rare allergic reactions including hives, swelling, or difficulty breathing.
Sudden severe stomach pain and bloody diarrhea indicating gastrointestinal ischemia.
Chest pain resembling heart attack symptoms requiring immediate medical evaluation.
Potential for elevated blood pressure and cardiac ischemic events in susceptible individuals.
Temporary paresthesias or sensations of pressure anywhere in the body.
Possible jaw or throat tightness that warrants prompt medical attention.
Infrequent but serious cardiovascular adverse events in patients with underlying heart disease.

Precautions

Do not use in patients with uncontrolled hypertension or significant cardiovascular disease.
Avoid use in patients with a history of stroke, transient ischemic attacks, or coronary artery disease.
Caution when prescribing to patients with risk factors for coronary artery disease (diabetes, smoking, family history).
Avoid concurrent use with MAO inhibitors or within 14 days of discontinuing such therapy.
Monitor blood pressure regularly during treatment due to potential hypertensive effects.
Use cautiously in patients with hepatic or renal impairment; dosage adjustment may be necessary.
Not recommended for use in patients under 18 years old (except nasal spray in those 12 and older).
Patients with phenylketonuria should exercise caution with orally disintegrating tablets containing phenylalanine.
Avoid use within 24 hours before or after triptans or ergotamine-containing drugs to prevent additive vasoconstriction.
Warn patients about potential impairment of mental alertness; caution with driving or operating machinery.
Reassess diagnosis if no response after initial migraine treatment with zolmitriptan.
Limit frequency of migraine attacks treated with zolmitriptan to avoid medication-overuse headaches.
Inform patients about signs and symptoms of serotonin syndrome if combined with other serotonergic medications.
Pregnancy and lactation safety have not been established; use only if clearly needed and prescribed by a healthcare provider.

Warnings

Contraindicated in patients with uncontrolled high blood pressure or significant ischemic heart disease.
Do not use with or within 14 days of monoamine oxidase inhibitors due to serious drug interactions.
Avoid use within 24 hours before or after other migraine medications including triptans and ergot derivatives.
Risk of serotonin syndrome when combined with other serotonergic agents such as antidepressants or opioids.
Not intended to prevent migraine attacks; only for acute treatment of existing migraine headaches.
May cause elevation of blood pressure to dangerous levels; monitor cardiovascular status regularly.
Do not exceed the maximum daily dose of 10 mg to avoid toxicity and adverse cardiovascular effects.
Risk of serious allergic reactions including angioedema and anaphylaxis, requiring emergency treatment.
Should not be used to treat headaches that differ from usual migraine pattern or present with neurological deficits.
Overuse may lead to medication-overuse headache, resulting in worsening headache frequency and severity.
Patients with a history of Wolff-Parkinson-White syndrome should not use zolmitriptan.
Use cautiously in elderly patients due to higher likelihood of underlying cardiovascular conditions.
Patients experiencing chest pain or signs of cardiac ischemia should seek immediate medical attention.

Contraindication

Known hypersensitivity or allergy to zolmitriptan or any component of the formulation.
Uncontrolled hypertension or severe cardiovascular disease including angina pectoris.
History of myocardial infarction, stroke, or transient ischemic attack (TIA).
Peripheral vascular disease causing ischemia or circulation problems.
Concomitant use or use within 14 days of monoamine oxidase inhibitors (MAOIs).
Use within 24 hours before or after other triptan or ergotamine preparations.
Presence of Wolff-Parkinson-White syndrome or other significant cardiac conduction abnormalities.
Migraine with hemiplegia or migraine presenting with prolonged neurological deficits.
Severe hepatic impairment may serve as a contraindication due to altered metabolism.
Use in children under 12 years of age due to lack of safety and efficacy data.
Patients with ischemic bowel disease or other severe vascular insufficiency conditions.

Drug Interactions

Co-administration with monoamine oxidase inhibitors (MAOIs) such as phenelzine or selegiline significantly increases zolmitriptan plasma levels and risk of toxicity.
Increased risk of serotonin syndrome when taken concurrently with SSRIs (e.g., fluoxetine, sertraline), SNRIs (e.g., venlafaxine, duloxetine), or other serotonergic drugs.
Concomitant use with ergot alkaloids (e.g., ergotamine, dihydroergotamine) may result in additive vasoconstrictive effects and ischemic complications.
Potential interaction with cimetidine, which may inhibit metabolism leading to increased zolmitriptan concentrations.
Use with other triptans (sumatriptan, rizatriptan) within 24 hours may cause excessive vasoconstriction.
Concurrent opioid use may potentiate serotonergic effects and increase risk of serotonin syndrome.
Certain antidepressants that affect CYP1A2 may alter zolmitriptan metabolism, requiring monitoring.
Interactions with medications that elevate blood pressure could exacerbate hypertension.
Concomitant use with antipsychotics or antiemetic agents that affect serotonin pathways should be monitored carefully.
Herbal supplements with serotonergic activity (e.g., St John's Wort) may increase risk of serotonin toxicity.
Use caution when combining with immunomodulators or other drugs affecting hepatic enzyme activity.
No significant interaction reported with common over-the-counter analgesics such as acetaminophen or NSAIDs.

Preparations Of The Drug

Oral tablets available in 1.25 mg and 2.5 mg doses; tablets are scored to allow half dosing of 1.25 mg.
Orally disintegrating tablets (Zomig-ZMT) supplied as 2.5 mg tablets, designed to dissolve rapidly in the mouth without water.
Nasal spray formulation delivering 2.5 mg dose per spray for rapid absorption via the nasal mucosa.
All dosage forms packaged with instructions to limit total daily dose to 10 mg.
Tablets and orally disintegrating formulations contain inactive ingredients that ensure stability and bioavailability.
Orally disintegrating tablets contain phenylalanine, important for patients with phenylketonuria to note.
Nasal spray delivered via metered-dose pump providing precise dosage control.
Preparations require storage at room temperature away from moisture, heat, and direct light to maintain potency.
Available both as brand name (Zomig) and generic zolmitriptan formulations.
Packaging includes clear patient instructions emphasizing correct timing and dose limits to prevent overdose.
Preparation forms allow flexibility in administration based on patient preference and clinical scenario.
Disintegrating tablet packaging designed to protect from moisture until use, with clear foil peel-back instructions.
Nasal spray preparation is particularly beneficial for patients with nausea or vomiting during migraine attacks.